ArticleQuantitative imaging in medicine and surgery2025
Fractal dimension as a predictive biomarker for tumor grade and cerebellar mutism syndrome in pediatric posterior fossa tumors.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fractal dimension (FD) analysis of preoperative magnetic resonance imaging (MRI) scans offers a potential approach to quantify tumor structural complexity, but its utility for predicting tumor grade and cerebellar mutism syndrome (CMS) risk in pediatric posterior fossa tumors remains unestablished. This study aimed to evaluate FD's dual utility as a biomarker for tumor grading and CMS prediction in pediatric posterior fossa tumors. Methods: A retrospective analysis was conducted on 247 pediatric patients diagnosed with posterior fossa tumors (97 with low-grade tumors and 150 with high-grade tumors; 74 with CMS and 173 without CMS) who underwent surgery at Beijing Children's Hospital and had preoperative MRI scans. FD was extracted using box-counting algorithms from both the tumor mask area (mFD) and the significant region area (sFD). The relationship between mFD and the World Health Organization (WHO) tumor grade was assessed, and the diagnostic performance of sFD in predicting CMS was also evaluated. Results: mFD demonstrated a strong ability to differentiate between high- and low-grade posterior fossa tumors, with an area under the curve (AUC) of 0.80, sensitivity of 78%, and specificity of 75%. Significant differences in mFD were observed between WHO grades: grade 4 [0.88 (0.82-0.94)] > grade 3 [0.79 (0.68-0.89), P=0.03], grade 3 > grade 2 [0.68 (0.48-0.76), P=0.008], and grade 4 > grade 1/2 (both P<0.01), but not between grades 1 and 2 (P=1.00). For CMS prediction, sFD was significantly higher in the CMS group (0.60±0.24) versus the non-CMS group (0.46±0.22, P<0.001). The receiver operating characteristic (ROC) analysis for using sFD to predict CMS revealed a sensitivity of 67%, specificity of 61%, and an AUC of 0.66. Multivariable analysis confirmed sFD as an independent predictor of CMS [odds ratio (OR): 11.70, 95% confidence interval (CI): 3.10-43.90, P<0.001]. Subgroup analyses showed improved CMS prediction in females (AUC =0.73, sensitivity 83%) and non-midline tumors (AUC =0.72, specificity 80%). Conclusions: FD appears to be a promising biomarker for predicting both the grade of posterior fossa tumors and the likelihood of developing CMS in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.